

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9989)**

**POLL RESULTS OF THE 2020 FOURTH EXTRAORDINARY  
GENERAL MEETING HELD ON DECEMBER 15, 2020**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, at the 2020 fourth extraordinary general meeting of the Company (the “**EGM**”) held at 2:30 p.m. on Tuesday, December 15, 2020 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, all the proposed resolutions set out in the notice of the EGM were passed by way of poll. For details of the resolutions considered at the EGM, the Shareholders may refer to the notice of the EGM dated November 24, 2020 and the circular of the EGM dated November 24, 2020 of the Company (the “**Circular**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of Share in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). No Shareholder was required to abstain from voting on the resolutions under the Listing Rules. There was no Share entitling the holder to attend the meeting and abstain from voting in favour of the resolutions under Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the People’s Republic of China and the Articles of Association.

**I. CONVENING OF THE MEETING**

The total number of Shares entitling the holders to attend and vote on the resolutions at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 997,904,295 Shares (including 974,273,260 A Shares and 23,631,035 H Shares), representing approximately 68.0097% of the total number of Shares.

## II. POLL RESULTS OF THE EGM

The poll results in respect of the respective resolutions at the EGM are set out below:

NO.	ORDINARY RESOLUTION	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.00	Proposal on the reappointment of accounting firms	994,406,195 (99.6495%)	3,498,100 (0.3505%)	0 (0.0000%)
NO.	SPECIAL RESOLUTIONS	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
2.00	Proposal on the application for credit line by the wholly-owned subsidiary to China Guangfa Bank and Industrial Bank and provision of guarantees by the Company	995,026,795 (99.7116%)	2,877,500 (0.2884%)	0 (0.0000%)
3.00	Proposal on the application for credit by the wholly-owned subsidiary to China Development Bank and provision of guarantees by the Company	995,026,795 (99.7116%)	2,877,500 (0.2884%)	0 (0.0000%)
4.00	Proposal on the credit line adjustment of Bank of China and provision of guarantees by the Company	995,041,795 (99.7131%)	2,862,500 (0.2869%)	0 (0.0000%)

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolution numbered 1, this resolution was duly passed as an ordinary resolution.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 2 to 4, these resolutions were duly passed as special resolutions.

By Order of the Board of Directors  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
December 15, 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*